
Research Update Biosergen: Licensing deal with Alkem and CTA submission

Carlsquare Equity Research has updated its view on Biosergen following the Licensing deal with Alkem Laboratories and the submitted CTA.

[Read the full update here.](#)

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

Contact

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst
niklas.elmhammer@carlsquare.com
+46 (0)70 898 39 59

Attachments

[Research Update Biosergen: Licensing deal with Alkem and CTA submission](#)